Use of Hepatitis B Core Antibody–Positive Liver Allograft in Hepatitis C Virus–Positive and –Negative Recipients With Use of Short Course of Hepatitis B Immunoglobulin and Lamivudine

Jain, Ashokkumar; Orloff, Mark S.; Abt, Peter L.; Kashyap, Randeep; Mohanka, Ravi; Lansing, K.; Kelley, Maurice L.; Bozorgzadeh, Adel

doi:10.1016/j.transproceed.2005.07.049

Cited by 26 publications

(48 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Jain et al, have also recently described the development of a YMDD mutant in 2 of 28 patients receiving anti-HBc (+) grafts despite the use of lamivudine indefinitely and HBIg (10 000 units daily for 4 days). This data emphasize the need to better define risk and to develop a more standard approach to using these grafts (15).…”

Section: Discussionmentioning

confidence: 88%

Case Report of Lamivudine-Resistant Hepatitis B Virus Infection Post Liver Transplantation from a Hepatitis B Core Antibody Donor

Yen¹,

Bonatti²,

Mendez

et al. 2006

American Journal of Transplantation

View full text Add to dashboard Cite

The use of allografts from donors with hepatitis B core antibody in liver transplantation (LT) is associated with the risk of de novo hepatitis B virus (HBV) infection. Prophylaxis using hepatitis B Immune globulin (HBIg) and lamivudine alone or in combination has been reported. Yet, there are no standardized regimens and long-term efficacy is not known. We report a case of a patient who underwent LT for alcoholic liver disease who received an allograft from a donor with Hepatitis B core antibody. The patient had no previous exposure to HBV, was vaccinated against HBV, and had demonstrated Hepatitis B surface antibody present in serum before and 6 months after transplantation. Prophylaxis with short-term HBIg (1 week) and indefinite lamivudine was given. De novo HBV infection developed more than 3 years after LT with a lamivudineresistant polymerase mutant containing the rtM204I and rtl180L/M mutations. We reviewed the risk of de novo post-LT HBV infection in recipients of livers from hepatitis B core antibody positive donors. High risk were HBV naïve recipients, moderate risk recipients had isolated hepatitis B surface antibody (anti-HBs) or hepatitis B core antibody (anti-HBc), while low-risk recipients had both anti-HBs and anti-HBc. We reviewed prophylaxis protocols reported in the literature and made recommendations for management.

show abstract

Section: Discussionmentioning

confidence: 88%

Case Report of Lamivudine-Resistant Hepatitis B Virus Infection Post Liver Transplantation from a Hepatitis B Core Antibody Donor

Yen¹,

Bonatti²,

Mendez

et al. 2006

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

“…Thus far, 3 strategies in this setting of adult liver transplant have been published, which include use of HBIG alone, [6][7][8] nucleoside analogue alone, [9][10][11] and both HBIG and nucleoside analogues. [12][13][14] Table 1 summarizes the results of these studies.…”

Section: Discussionmentioning

confidence: 99%

“…Prophylactic therapy can include either hepatitis B immunoglobulin (HBIG), [6][7][8] or a nucleoside analogue alone, [9][10][11] or a combination of HBIG and nucleoside analogues. [12][13][14] In this article, we present 2 cases of hepatitis B-naïve recipients who received HBcAb-positive grafts and who developed de novo hepatitis B infection during prophylaxis with HBIG alone, as well as a review of the literature.…”

Section: Introductionmentioning

confidence: 99%

Untitled

Shin

Chang²

2016

Exp Clin Transplant

View full text Add to dashboard Cite

Tests were negative; however, both patients recently became hepatitis B surface antigen positive. Other laboratory results, including liver function test, were unremarkable, except HBsAb titer was undetectable even though hepatitis B immunoglobulin monotherapy had been administrated 2 months previously in both patients. The patients had hepatitis B virus DNA levels of 3.07E+08 copies/mL and 1.51E+08 copies/mL. We suggest that additional prophylactic therapies above hepatitis B immunoglobulin monotherapy are needed for these recipients.

show abstract

“…Angus/2008 [32] Avolio/2008 [106] Angus/2000 [51] Anselmo/2002 [33] Anderson/2007 [107] Alonso/2003 [108] Brock/2011 [109] Buti/2003 [110] Ben-Ari/2004 [111] Chun/2010 [112] Dadson/2000 [113] Dehghani/2013 [114] Dickson/2006 [59] Dumortier/2003 [115] Degertekin/2010 [116] Di Paolo/2004 [117] Faust/2003 [118] Freshwater/2008 [99] Fabrega/2003 [119] Feretti/2004 [120] Filipponi/2010 [121] Gane/2013 [55] Han/2000 [35] Han/2003 [122] Honaker/2002 [123] Iacob/2008 [124] Jiang/2010 [125] Jain/2005 [126] Jiao/2007 [127] Karademir/2006 [128] Kwon/2006 [129] Lee/2000 [130] Lee/2004 [131] Lu/2004 [85] Lu/2008 [39] Loss/2003 [132]…”

Section: Authormentioning

confidence: 99%

Controversies Regarding the Hepatitis B Immune Globulin Prophylaxis (HBIG) for Liver Transplantation Recipients

Jazayeri

Rizzetto²,

Alavian

2014

Journal of Gastroenterology and Hepatology Research

View full text Add to dashboard Cite

Use of Hepatitis B Core Antibody–Positive Liver Allograft in Hepatitis C Virus–Positive and –Negative Recipients With Use of Short Course of Hepatitis B Immunoglobulin and Lamivudine

Cited by 26 publications

References 6 publications

Case Report of Lamivudine-Resistant Hepatitis B Virus Infection Post Liver Transplantation from a Hepatitis B Core Antibody Donor

Case Report of Lamivudine-Resistant Hepatitis B Virus Infection Post Liver Transplantation from a Hepatitis B Core Antibody Donor

Untitled

Controversies Regarding the Hepatitis B Immune Globulin Prophylaxis (HBIG) for Liver Transplantation Recipients

Contact Info

Product

Resources

About